Ascend Wellness Holdings (AAWH) Liabilities and Shareholders Equity (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Liabilities and Shareholders Equity came in at $872.1 million in Q1 2026, down 4.87% year-on-year from $916.7 million in Q1 2025, and down 3.95% quarter-over-quarter from $907.9 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $872.1 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 4.87% year-over-year to $872.1 million in Q1 2026; TTM through Mar 2026 was $2.7 billion, a 26.3% decrease from a year earlier, with the FY2025 full-year figure at $907.9 million, up 0.83% from the prior year.
- Liabilities and Shareholders Equity retreated to $872.1 million in Q1 2026 per AAWH's latest filing, from $907.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $929.4 million in Q2 2024 and bottomed at $407000.0 in Q3 2025.
- The 5-year median for Liabilities and Shareholders Equity is $899.6 million (2023), against an average of $829.9 million.
- Across the five-year window, Liabilities and Shareholders Equity surged 48.39% in 2022 and sank 99.95% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $872.2 million in 2022, then rose by 5.43% to $919.6 million in 2023, then decreased by 2.08% to $900.4 million in 2024, then increased by 0.83% to $907.9 million in 2025, then fell by 3.95% to $872.1 million in 2026.
- Per Business Quant, the three latest AAWH Liabilities and Shareholders Equity figures stand at $872.1 million (Q1 2026), $907.9 million (Q4 2025), and $407000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn | 872.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 872.09 Mn |
| Dec 31, 2025 | 907.93 Mn |
| Sep 30, 2025 | 407,000.00 |
| Jun 30, 2025 | 903.87 Mn |
| Mar 31, 2025 | 916.73 Mn |
| Dec 31, 2024 | 900.43 Mn |
| Sep 30, 2024 | 895.87 Mn |
| Jun 30, 2024 | 929.36 Mn |
| Mar 31, 2024 | 921.86 Mn |
| Dec 31, 2023 | 919.55 Mn |
| Sep 30, 2023 | 907.99 Mn |
| Jun 30, 2023 | 899.56 Mn |
| Mar 31, 2023 | 870.09 Mn |
| Dec 31, 2022 | 872.16 Mn |
| Sep 30, 2022 | 847.21 Mn |
| Jun 30, 2022 | 828.79 Mn |
| Mar 31, 2022 | 714.20 Mn |
| Dec 31, 2021 | 723.44 Mn |
| Sep 30, 2021 | 716.88 Mn |
| Jun 30, 2021 | 578.76 Mn |